Cogent's stock surged 124% to $33.20 on high trading volume. Phase 3 trial showed bezuclastinib improved survival rates in GIST. Combination therapy reached median PFS of 16.5 months, significantly better than sunitinib. COGT plans NDA submission to the FDA in early 2026. Company anticipates presenting detailed trial results at a major conference in 2026.
COGT shows 56% TSS improvement in non-advanced systemic mastocytosis patients. 76% of patients had over 50% symptom reduction in 24 weeks. Bezuclastinib leads to rapid reductions in serum tryptase levels. Enrollment in SUMMIT Part 2 study is complete with 179 patients. Stock price increased by 10.60%, closing at $9.83.
